HHS National Institute of Allergy & Infectious Diseases: As Prevention Strategy for Sexually Transmitted Infections Rolls Out, Experts Highlight Both Promise, Knowledge Gaps
January 07, 2025
January 07, 2025
WASHINGTON, Jan. 7 (TNSres) -- The U.S. Department of Health and Human Services National Institute of Allergy and Infectious Diseases issued the following news release:
* * *
Doxycycline has Population-Level Benefits, Warrants Vigilance for Antimicrobial Resistance
* * *
As health care services begin offering doxycycline to prevent bacterial sexually transmitted infections (STIs), real-world evidence demonstrates that the postexposure strategy, . . .
* * *
Doxycycline has Population-Level Benefits, Warrants Vigilance for Antimicrobial Resistance
* * *
As health care services begin offering doxycycline to prevent bacterial sexually transmitted infections (STIs), real-world evidence demonstrates that the postexposure strategy, . . .